Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
-
Immuneering to Present at the Leerink Global Healthcare Conference
-
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
-
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
-
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Janu
-
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial, Securing Alignment with FDA and EMA
-
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
-
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
-
- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million...
-
- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday,...